Transamerica Financial Advisors’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Transamerica Financial Advisors’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-1	Closed	-$1K	–	666
2023 Q3	$1K	Hold	1	–	–	﹤0.01%	649
2023 Q2	$1K	Hold	1	–	–	﹤0.01%	622
2023 Q1	$1K	Hold	1	–	–	﹤0.01%	607
2022 Q4	$1K	Hold	1	–	–	﹤0.01%	702
2022 Q3	$1K	Hold	1	–	–	﹤0.01%	651
2022 Q2	$1K	Buy	+1	New	+$95	﹤0.01%	665
2016 Q1	–	Sell	-2,394	Closed	-$52K	–	877
2015 Q4	$52K	Sell	2,394 -2,050	-46%	-$39.9K	﹤0.01%	400
2015 Q3	$89K	Buy	4,444 +681	+18%	+$21.5K	0.01%	332
2015 Q2	$131K	Buy	3,763 +3,148	+512%	+$96.1K	0.01%	365
2015 Q1	$16K	Buy	+615	New	+$11.3K	﹤0.01%	573

Other funds holding HZNP

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

BTI

Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

VWA

Valued Wealth Advisors Holladay, Utah $275M AUM 24.94% 1-Year Est. Return

FSWA

Financial Synergies Wealth Advisors Houston, Texas $1.18B AUM 31.41% 1-Year Est. Return

BCMLT

Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $683M AUM 22.58% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Transamerica Financial Advisors's HZNP Position: Q4 2023 in Review

Transamerica Financial Advisors sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 1 share — an estimated $1K sold.

Transamerica Financial Advisors first reported a position in HZNP in Q1 2015 and held it in 10 quarters. The position peaked at $131K in Q2 2015. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

Transamerica Financial Advisors reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
Transamerica Financial Advisors sold 1 Horizon Therapeutics Public Limited Company Ordinary Shares share in Q4 2023, an estimated $1K.
Transamerica Financial Advisors first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2015 and held it in 10 quarters.
Transamerica Financial Advisors's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $131K in Q2 2015.
6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on Transamerica Financial Advisors's 13F filing for Q4 2023, filed 12 Feb 2024.